STRATA Skin Sciences Expands Reimbursement Eligibility For Excimer Laser Treatments To Include Multiple Inflammatory And Auto-Immune Skin Conditions Beyond Original Psoriasis Indication

STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions (May 2025: CPT® Editorial Summary of Panel Actions | AMA) has accepted revision to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects over 20 years of clinical evidence and real-world use of STRATA's XTRAC® Excimer Lasers, a safe, effective, non-drug treatment for patients with chronic inflammatory and autoimmune skin diseases.

The updated CPT descriptor aligns the codes with current FDA clearances and commercial payer coverage guidelines. The changes are anticipated to reduce systemic denials and the need for prior authorizations. Further, the revised language now explicitly includes the treatment of inflammatory and autoimmune skin conditions, enabling coverage for conditions such as vitiligo, atopic dermatitis, mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-cell lymphoma (CTCL). While currently with more than one million patients having been treated over the last 20 years, only 30% of excimer laser procedures treat non-psoriasis conditions (based on 2023 Medicare data) as these require additional pre-authorization processing.  

This change is expected to expand direct and clear reimbursement path and domestic market access from the roughly 10 million psoriasis patients covered today, to over 30 million potential patients, without the need to individually seek pre-determination of coverage.